← Leaderboards
Thomas G. Forsthuber
University Of Texas San Antonio
$6,890,687
Attributed
$7,090,816
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $584.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,090,816 · 10
By mechanism
R01$5,076,594 · 4
R21$1,619,592 · 4
R29$226,824 · 1
G12$167,806 · 1
Top collaborators
- Stephan B. H. Bach2 shared
Most similar at University Of Texas San Antonio
Same institution · by research overlap
- Stephan B. H. Bach$200,129
Others in their field
Top investigators on “Multiple Sclerosis”
- David A. Hafler · Brigham And Women'S Hospital$33,720,341
- Vijay K Kuchroo · Brigham And Women'S Hospital$32,935,587
- Stephen L Hauser · University Of California San Francisco$32,469,388
- Katerina Akassoglou · University Of California San Diego$24,525,425
- Abdolmohamad Rostami · Thomas Jefferson University$23,969,638
- Stephen D Miller · Northwestern University$23,969,272
Research focus
Multiple SclerosisCellsExperimental Autoimmune EncephalomyelitisCytokineInflammatoryT-LymphocyteDisease ProgressionReportingAntigen PresentationMediatingPreventAutoimmune DiseasesCell TypeChronicPlayMyelinEnzyme Linked Immunosorbent AssayPre-ClinicalLaboratory MouseInterleukin 5Interleukin 4NeuronsInterleukin 2Anti-Inflammatory Agents
Grant awards (30)
The role of TNFR2 in ameliorating progressive encephalomyelitis$337,715
R01 · FY2025 · NS · contact PI
Investigating changes in myelin lipid composition during relapsing-remitting neuroinflammation$181,379
R21 · FY2025 · NS · contact PI
The role of TNFR2 in ameliorating progressive encephalomyelitis$365,906
R01 · FY2024 · NS · contact PI
Investigating changes in myelin lipid composition during relapsing-remitting neuroinflammation$218,879
R21 · FY2024 · NS · contact PI
The role of TNFR2 in ameliorating progressive encephalomyelitis$378,743
R01 · FY2023 · NS · contact PI
The role of TNFR2 in ameliorating progressive encephalomyelitis$378,743
R01 · FY2022 · NS · contact PI
The role of TNFR2 in ameliorating progressive encephalomyelitis$378,743
R01 · FY2021 · NS · contact PI
Eliminating autoantibody-producing plasma cells in neuroinflammation via ERK inhibition$187,084
R21 · FY2020 · AI · contact PI
Eliminating autoantibody-producing plasma cells in neuroinflammation via ERK inhibition$223,750
R21 · FY2019 · AI · contact PI
Predictive biomarkers for EAE development$183,750
R21 · FY2015 · NS · contact PI
MIF inhibition as a novel treatment for autoimmune myocarditis$183,750
R21 · FY2015 · AI · contact PI
MIF inhibition as a novel treatment for autoimmune myocarditis$220,500
R21 · FY2014 · AI · contact PI
Predictive biomarkers for EAE development$220,500
R21 · FY2014 · NS · contact PI
BIOMARKER DISCOVERY IN GLUCOCORTICOID RESISTANCE IN EAE$167,806
G12 · FY2011 · RR · contact PI
Steroid resistance: Experimental Autoimmune Encephalomyelitis/Multiple Sclerosis$275,792
R01 · FY2010 · NS · contact PI
Steroid resistance: Experimental Autoimmune Encephalomyelitis/Multiple Sclerosis$278,578
R01 · FY2009 · NS · contact PI
Steroid resistance: Experimental Autoimmune Encephalomyelitis/Multiple Sclerosis$105,131
R01 · FY2009 · NS · contact PI
Steroid resistance: Experimental Autoimmune Encephalomyelitis/Multiple Sclerosis$278,578
R01 · FY2008 · NS · contact PI
Steroid resistance: Experimental Autoimmune Encephalomyelitis/Multiple Sclerosis$278,578
R01 · FY2007 · NS · contact PI
Avidity Maturation of T Cells in Mutiple Sclerosis$235,244
R01 · FY2005 · NS
Avidity Maturation of T Cells in Mutiple Sclerosis$254,363
R01 · FY2004 · NS
HUMAN CARTILAGE GP39 IN HLA-DR4 TRANSGENIC MURINE MODEL$257,732
R01 · FY2003 · AR
Avidity Maturation of T Cells in Mutiple Sclerosis$254,363
R01 · FY2003 · NS
Avidity Maturation of T Cells in Mutiple Sclerosis$35,000
R01 · FY2003 · NS
Avidity Maturation of T Cells in Mutiple Sclerosis$254,363
R01 · FY2002 · NS
HUMAN CARTILAGE GP39 IN HLA-DR4 TRANSGENIC MURINE MODEL$250,225
R01 · FY2002 · AR
HUMAN CARTILAGE GP39 IN HLA-DR4 TRANSGENIC MURINE MODEL$242,935
R01 · FY2001 · AR
TH1/TH2 IMMUNITY IN YOUNG ADULT AND AGED MICE$115,636
R29 · FY2001 · AI
HUMAN CARTILAGE GP39 IN HLA-DR4 TRANSGENIC MURINE MODEL$235,862
R01 · FY2000 · AR
TH1/TH2 IMMUNITY IN YOUNG ADULT AND AGED MICE$111,188
R29 · FY2000 · AI